Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys

Shuang Wang, Yun Peng, Rongjuan Wang, Shasha Jiao, Min Wang, Weijin Huang, Chao Shan, Wen Jiang, Zepeng Li, Chunying Gu, Ben Chen, Xue Hu, Yanfeng Yao, Juan Min, Huajun Zhang, Ying Chen, Ge Gao, Peipei Tang, Gang Li, An Wang, Lan Wang, Jinchao Zhang, Shuo Chen (), Xun Gui (), Zhiming Yuan () and Datao Liu ()
Additional contact information
Shuang Wang: Mabwell (Shanghai) Bioscience Co., Ltd
Yun Peng: Chinese Academy of Sciences
Rongjuan Wang: Mabwell (Shanghai) Bioscience Co., Ltd
Shasha Jiao: Mabwell (Shanghai) Bioscience Co., Ltd
Min Wang: Mabwell (Shanghai) Bioscience Co., Ltd
Weijin Huang: National Institutes for Food and Drug Control
Chao Shan: Chinese Academy of Sciences
Wen Jiang: Mabwell (Shanghai) Bioscience Co., Ltd
Zepeng Li: Mabwell (Shanghai) Bioscience Co., Ltd
Chunying Gu: Mabwell (Shanghai) Bioscience Co., Ltd
Ben Chen: Mabwell (Shanghai) Bioscience Co., Ltd
Xue Hu: Chinese Academy of Sciences
Yanfeng Yao: Chinese Academy of Sciences
Juan Min: Chinese Academy of Sciences
Huajun Zhang: Chinese Academy of Sciences
Ying Chen: Chinese Academy of Sciences
Ge Gao: Chinese Academy of Sciences
Peipei Tang: Mabwell (Shanghai) Bioscience Co., Ltd
Gang Li: Mabwell (Shanghai) Bioscience Co., Ltd
An Wang: Mabwell (Shanghai) Bioscience Co., Ltd
Lan Wang: National Institutes for Food and Drug Control
Jinchao Zhang: Mabwell (Shanghai) Bioscience Co., Ltd
Shuo Chen: University of Oxford
Xun Gui: Mabwell (Shanghai) Bioscience Co., Ltd
Zhiming Yuan: Chinese Academy of Sciences
Datao Liu: Mabwell (Shanghai) Bioscience Co., Ltd

Nature Communications, 2020, vol. 11, issue 1, 1-8

Abstract: Abstract Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor. Crosslinking of Fc with FcγRIIB mediates antibody-dependent enhancement (ADE) activity by MW05. This activity is eliminated by introducing the LALA mutation to the Fc region (MW05/LALA). Potent prophylactic and therapeutic effects against SARS-CoV-2 are observed in rhesus monkeys. A single dose of MW05/LALA blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting. These results pave the way for the development of MW05/LALA as an antiviral strategy for COVID-19.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-19568-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19568-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-19568-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().